Jax DiEugenio

The EC approved glofitamab with gemcitabine/oxaliplatin for patients with relapsed or refractory diffuse large B-cell lymphoma, ineligible for ASCT.

Daratumumab reduced the risk of disease progression or death vs active monitoring in high-risk smoldering multiple myeloma.

Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.

Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.

Michael J. Morris, MD, discusses the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in PSMA-positive mCRPC.

The ZEISS INTRABEM 700 platform received 510(k) clearance from the FDA for use in neuro-oncology and breast cancer surgery.

Belzupacap sarotalocan demonstrated a favorable safety profile and early signs of biological activity in patients with NMIBC.

The European Commission approved subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma, regardless of transplant eligibility.

Jennifer Chan, MD, underscores the importance of early NET diagnosis in young adult and pediatric patients.

Rachel N. Grisham, MD, discusses the preliminary results of avutometinib plus defactinib in mesonephric and mesonephric-like cancers.

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

Obe-cel showed higher response rates and longer survival vs non–CAR T therapies in adults with R/R B-ALL.

TDI01, a selective ROCK2 inhibitor, generated responses and clinical benefit in patients with cGVHD.

CHMP recommends EU approval of acalabrutinib plus chemoimmunotherapy for untreated mantle cell lymphoma.

Relacorilant plus nab-paclitaxel demonstrated improved PFS and OS in platinum-resistant ovarian cancer.

Jeffrey Zonder, MD, emphasizes the importance of identifying MGUS and evaluating nonspecific symptoms to improve the detection of multiple myeloma.

Kelly E. McCann, MD, discusses mentorship, sponsorship, and work-life balance in oncology, highlighting strategies for supporting women in the field.

Tisotumab vedotin has received Japanese approval for advanced cervical cancer following chemotherapy.

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights advances in T-cell–redirecting therapies in the space.

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights symptom recognition and precursor conditions for the malignancy.

A randomized trial found no significant differences in recurrence or survival with smaller radiation margins vs standard RTOG protocols in patients with HGG.

A Type II variation application has been submitted to the EMA for the expanded approval of sugemalimab for unresectable stage III NSCLC.

Joshua Feinberg, MD, discusses the role of the Scout AI platform in aiding trial matching and treatment selection in oncology.

Kelly E. McCann, MD, discusses mentorship in oncology and the importance of guiding patients with breast cancer through their treatment journey.

Grzegorz S. Nowakowski, MD, discusses the FDA approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL.

Ocular adverse effects stemming from mirvetuximab soravtansine did not significantly affect HRQOL in FRα-positive platinum-resistant ovarian cancer.

Penpulimab received NMPA approval for first-line use with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma.

Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Puxitatug samrotecan demonstrated preliminary efficacy and manageable safety in advanced or metastatic endometrial cancer.

Neal D. Shore, MD, FACS, discusses the evaluation of nadofaragene firadenovec in intermediate-risk NMIBC and its potential effect on treatment strategies.